For the quarter ended March 2026, Gilead Sciences (GILD Quick QuoteGILD - Free Report) reported revenue of $6.96 billion, up 4.4% over the same period last year. EPS came in at $2.03, compared to $1.81 in the year-ago quarter.

The reported revenue represents a surprise of +0.95% over the Zacks Consensus Estimate of $6.89 billion. With the consensus EPS estimate being $1.89, the EPS surprise was +7.68%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Oncology- Trodelvy- U.S.: $253 million compared to the $222.88 million average estimate based on three analysts. The reported number represents a change of +39.8% year over year.
• Product Sales- Liver Disease- Other Liver Disease- U.S.: $15 million compared to the $157.8 million average estimate based on three analysts. The reported number represents a change of -77.9% year over year.
• Product Sales- Liver Disease- Vemlidy- U.S.: $91 million compared to the $104.18 million average estimate based on three analysts. The reported number represents a change of -9% year over year.
• Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.: $141 million versus the three-analyst average estimate of $121.36 million. The reported number represents a year-over-year change of -15.1%.
• Total product sales- Total: $6.95 billion compared to the $6.83 billion average estimate based on five analysts. The reported number represents a change of +5% year over year.
• Revenues- Royalty contract and other revenues: $14 million compared to the $42.52 million average estimate based on five analysts. The reported number represents a change of -74.1% year over year.
• Product Sales- Liver Disease- Vemlidy- Total: $237 million versus the four-analyst average estimate of $221.37 million. The reported number represents a year-over-year change of -6%.
• Product Sales- Oncology- Cell Therapy- Yescarta- Total: $332 million compared to the $364.23 million average estimate based on four analysts. The reported number represents a change of -14% year over year.
• Product Sales- HIV- Biktarvy- Total: $3.36 billion versus $3.3 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.7% change.
• Product Sales- HIV- Symtuza-Revenue share- Total: $138 million compared to the $112.33 million average estimate based on four analysts. The reported number represents a change of +21.1% year over year.
• Product Sales- Veklury- Total: $144 million compared to the $182.98 million average estimate based on four analysts. The reported number represents a change of -52.3% year over year.
• Product Sales- HIV- Odefsey- Total: $221 million compared to the $240.94 million average estimate based on four analysts. The reported number represents a change of -21.4% year over year.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned -3.7% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.